Surveillance of screening-detected cancers (colon and rectum, breast, and cervix) - United States, 2004-2006 by German, Robert R. et al.
Morbidity and Mortality Weekly Report
w w w . c d c . g o v / m m w r
Surveillance Summaries November 26, 2010 /  Vol. 59 /  No. SS-9
Surveillance of Screening-Detected Cancers 
(Colon and Rectum, Breast, and Cervix) — 
United States, 2004-2006
d e p a r t m e n t  o f  H e a l t h  a n d  h u m a n  s e r v i c e s  
c e n t e r s  f o r  D i s e a s e  C o n t r o l  a n d  P r e v e n t i o n
M M W R
The M M W R  series o f  publications is published by the Office o f 
Surveillance, Epidemiology, and Laboratory Services, Centers for 
Disease Control and Prevention (CD C), U.S. D epartm ent o f  Health 
and H um an Services, Atlanta, GA 30333.
Suggested Citation: Centers for Disease Control and Prevention. 
[Title]. M M W R  2010;59(No. SS-#):[inclusive page numbers].
C e n t e r s  f o r  D is e a s e  C o n t r o l  a n d  P r e v e n t i o n
Thomas R. Frieden, M D , M PH  
Director 
H arold  W. Jaffe, M D , M A 
Associate Director fo r  Science 
James W. Stephens, PhD  
Office o f  the Associate Director fo r  Science 
Stephen B. Thacker, M D , MSc 
Deputy Director fo r  
Surveillance, Epidemiology, and Laboratory Services 
Stephanie Zaza, M D , M PH  
Director, Epidemiology and Analysis Program Office
E d i t o r ia l  a n d  P r o d u c t i o n  S t a f f
Ronald L. Moolenaar, M D , M PH  
Editor, M M W R  Series 
Teresa F. Rutledge 
M anaging Editor, M M W R  Series 
David C. Johnson 
Lead Technical Writer-Editor 
Jeffrey D. Sokolow, MA 
Project Editor 
M artha F. Boyd 
Lead Visual Information Specialist 
Malbea A. LaPete 
Stephen R. Spriggs 
Terraye M . Starr 
Visual Information Specialists 
Q uang M . Doan, MBA 
Phyllis H . King 
Information Technology Specialists
___________________ E d i t o r ia l  B o a r d ___________________
W illiam L. Roper, M D , M PH , Chapel Hill, N C , Chairm an 
Virginia A. Caine, M D , Indianapolis, IN 
Jonathan E. Fielding, M D , M PH , MBA, Los Angeles, CA 
David W. Fleming, M D , Seattle, WA 
W illiam  E. Halperin, M D , D rPH , M PH , Newark, NJ 
King K. Holmes, M D , PhD , Seattle, WA 
Deborah Holtzm an, PhD , Atlanta, GA 
John  K. Iglehart, Bethesda, M D  
Dennis G. Maki, M D , M adison, W I 
Patricia Quinlisk, M D , M PH , Des Moines, IA 
Patrick L. Remington, M D , M PH , M adison, W I 
Barbara K. Rimer, D rPH , Chapel Hill, N C  
John  V. Rullan, M D , M PH , San Juan, PR 
W illiam  Schaffner, M D , Nashville, T N  
A nne Schuchat, M D , Atlanta, GA 
Dixie E. Snider, M D , M PH , Atlanta, GA 
John W. Ward, M D , Atlanta, GA
C O N T E N T S
In tro d u c tio n .........................................................................................................  1




Vol. 59  /  SS-9 Surveillance Sum m aries 1
S u rv e illa n c e  o f  S c re e n in g -D e te c te d  C ancers  (C o lon  a n d  R ectum , 
B re a s t, a n d  C e rv ix )  — U n ite d  S ta te s , 2 0 0 4 - 2 0 0 6
S. Jane Henley, M SPH 
Jessica B. King, M PH  
Robert R. Germ an, D rPH  
Lisa C. Richardson, M D  
Marcus Plescia, M D
Division o f  Cancer Prevention and Control, N ational Center fo r  Chronic Disease Prevention and Health Promotion
Abstract
Problem /C ondition: Population-based screening is conducted to detect diseases or other conditions in persons before 
symptoms appear; effective screening leads to early detection and treatment, thereby reducing disease-associated mor­
bidity and mortality. Based on systematic reviews of the evidence of the benefits and harms and assessments o f the net 
benefit o f screening, the U.S. Preventive Services Task Force (USPSTF) recommends population-based screening for 
colon and rectum cancer, female breast cancer, and uterine cervix cancer. Few publications have used national data to 
examine the stage at diagnosis of these screening-amenable cancers.
R eporting Period Covered: 2004—2006.
D escription o f  Systems: Data were obtained from cancer registries affiliated with C D C ’s National Program of Cancer 
Registries (NPCR) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. 
Combined data from the N PC R  and SEER programs provide the best source of information on national population-based 
cancer incidence. Data on cancer screening were obtained from the Behavioral Risk Factor Surveillance System. This report 
provides stage-specific cancer incidence rates and screening prevalence by demographic characteristics and U.S. state.
Results: Approximately half of colorectal and cervical cancer cases and one third of breast cancer cases were diagnosed 
at a late stage of disease. Incidence rates of late-stage cancer differed by age, race/ethnicity, and state. Incidence rates 
of late-stage colorectal cancer increased with age and were highest among black men and women. Incidence rates of 
late-stage breast cancer were highest among women aged 60—79 years and black women. Incidence rates o f late-stage 
cervical cancer were highest among women aged 50—79 years and Hispanic women. The percentage o f persons who 
received recommended screening differed by age, race/ethnicity, and state.
In terpretation: Differences in late-stage cancer incidence rates might be explained partially by differences in screening use.
Public H ealth  Action: The findings in this report emphasize the need for ongoing population-based surveillance and 
reporting to monitor late-stage cancer incidence trends. Screening can identify colorectal, cervical, and breast cancers 
in earlier and more treatable stages o f disease. Multiple factors, including individual characteristics and health behaviors 
as well as provider and clinical systems factors, might account for why certain populations are underscreened. Cancer 
control planners, including comprehensive cancer-control programs, can use late-stage cancer incidence and screening 
prevalence data to identify populations that would benefit from interventions to increase screening utilization and to 
m onitor performance of early detection programs.
In tro d u ctio n
Population-based screening for cancer requires screening 
persons who might be at risk for but do not display symptoms 
of a particular cancer (1). Effective cancer screening reduces, 
through early detection and treatm ent, disease-associated
morbidity and mortality (2—4). Screening also helps prevent 
cancer by detecting precancerous lesions (e.g., colorectal 
adenomatous polyps and cervical intraepithelial neoplasia) 
that can be removed. Based on systematic reviews o f the evi­
dence of the benefits and harms and assessments of the net 
benefit o f screening, the U.S. Preventive Services Task Force 
(USPSTF) recommends population-based screening for colon 
and rectum cancer, female breast cancer, and uterine cervix 
cancer (5). Sponsored by the Agency for Healthcare Research 
and Quality, USPSTF is an independent panel of experts in 
prevention and primary care that systematically reviews the
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scientific evidence of the effectiveness of clinical preventive 
services, including screening for cancer, and develops recom­
mendations for these services. USPSTF grades the strength of 
evidence as follows: “A” (strongly recommends), “B” (recom­
mends), “C ” (offers no recommendation for or against), “D ” 
(recommends against), or “I” (finds insufficient evidence to 
recommend for or against) (5).
Progress against cancer can be measured by reductions in 
cancer mortality and also by trends in detecting cancer at earlier 
and more treatable stages of disease (6). Surveillance informa­
tion about the stage of cancer at diagnosis is useful because it 
in part reflects prevalence and quality o f screening (7).
Colorectal cancer is the third most commonly diagnosed 
cancer in both men and women in the United States (8). 
Incidence increases with age and is higher among men than 
among women and among blacks than among whites (9). 
The 5-year survival rate for persons who received a diagnosis 
of localized colorectal cancer is 91%, compared with 70% for 
regional-stage cancer and 11% for distant-stage cancer* (10). 
Studies of colorectal cancer show that black men and women 
are more likely to receive a diagnosis of late-stage disease than 
men and women in other racial/ethnic populations (11,12). 
Colorectal cancer incidence rates have been decreasing since 
1985, most markedly during 1998—2005, partially as a result 
of increases in screening (8). Screening for colorectal cancer 
has been proven to reduce mortality through detection of 
adenomatous polyps before they progress to cancer as well as 
detection of early-stage cancer (2,13). USPSTF recommends 
that men and women o f average risk begin regular colorectal 
cancer screening at age 50 years with any of three tests: a fecal 
occult blood test (FOBT) every year, a flexible sigmoidoscopy 
every 5 years, or a colonoscopy every 10 years (2,14). This is 
an “A” recommendation. The willingness of adults to utilize 
these tests depends on multiple factors, including individual 
disease risk, personal preference, and physician recommenda­
tion (15). Colorectal cancer screening rates are lower among 
persons aged 50—59 years, those with less education, and 
recent immigrants (13,16). Additionally, insurance coverage 
and geographic distance from a screening facility might affect 
a person’s decision to obtain screening (15,16).
Breast cancer is the most commonly diagnosed cancer in 
women and a leading cause of premature mortality (8). The 
5-year survival rate for women who receive a diagnosis of local­
ized breast cancer is 98%, compared with 84% for regional 
stage and 23% for distant stage (10). Mammography can detect 
breast cancer at an early stage, when treatment is most effec­
tive (3). The incidence o f female breast cancer increased from
* A  localized cancer is one that is confined to the prim ary site, a regional cancer 
is one th a t has spread directly beyond the  prim ary site or to regional lymph 
nodes, and a distant cancer is one that has spread to other organs.
1980-1999, due in part to the increased detection of localized 
disease and small (<2 cm) tumors by mammography, the use of 
which more than doubled during this period (17). Since 1999, 
breast cancer incidence has decreased, partially because the use 
of mammography has stabilized and screening in the 1980s 
and 1990s had detected many undiagnosed prevalent cases, 
and because after 2002 many women stopped using hormone 
replacement therapy (17). Widespread use o f screening and 
advances in treatment have resulted in substantial reductions 
in breast cancer mortality (18). USPSTF recommends bien­
nial screening mammography for women aged 50—74 years 
(19). This is a “B” recommendation. The lowest prevalence 
of recommended breast cancer screening is among women 
who lack health insurance, Asian/Pacific Islander (API) and 
American Indian/Alaska Native (AI/AN) women, and recent 
immigrants (20,21).
The dramatic decrease in cervical cancer incidence and 
mortality since the mid-20th century has been termed one of 
the nation’s foremost health success stories (22). This decrease 
is attributed to the convergence of three factors: an innovative 
breakthrough (the Pap test), public health promotion of the 
Pap test to women and to providers, and the routine use of 
the Pap test in primary-care practice (22). Although dramatic 
declines in cervical cancer mortality have occurred, nearly all 
cervical cancer cases could be prevented, and this cancer still 
ranks in the top 10 diagnosed cancers for black, AI/AN and 
Hispanic women and the 13th most common cancer among 
all women (8). Survival after cervical cancer diagnosis depends 
on stage at diagnosis; the 5-year survival rate for women 
who have localized disease is 92%, compared with 58% for 
regional disease and 17% for distant disease (10). Cervical 
cancer is diagnosed at a later stage more often in women aged 
>50 years, black women, and women who have not had a Pap 
test during the preceding 5 years (23,24). The Pap test detects 
cervical cancer and precancerous lesions (4). USPSTF recom­
mends that women begin screening for cervical cancer with 
the Pap test within 3 years of onset of sexual activity or at age 
21 years (whichever comes first) and be screened with three 
consecutive normal annual Pap tests and then at least every 3 
years up to age 64 years (25). This is an “A” recommendation. 
Because the primary cause o f cervical cancer is infection with 
certain types of hum an papillomavirus (HPV), HPV  testing 
has been advanced as an alternative or adjunct to primary Pap 
screening. The USPSTF concluded in 2003 that the evidence 
was insufficient to recommend for or against the routine use 
o f HPV testing as a primary screening for cervical cancer; this 
is an “I” recommendation (25). Prevalence of screening using 
the Pap test is lowest among women who lack health insurance, 
women with specific health risks such as smoking or being
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overweight or obese, women aged >65 years, API women, and 
recent immigrants (21,26,27).
This report provides incidence rates for late-stage cancers 
of the colon and rectum in men and women aged >50 years, 
o f the breast in women aged >50 years, and of the cervix 
in women aged >20 years on the basis o f data from cancer 
registries affiliated with C D C ’s National Program of Cancer 
Registries (NPCR) and the National Cancer Institute (NCI)’s 
Surveillance, Epidemiology, and End Results (SEER) program. 
This report also presents prevalence of recommended screen­
ing for these cancers based on data from the Behavioral Risk 
Factor Surveillance System (BRFSS), a state-based, ongoing 
telephone survey of adults aged >18 years (28).
M e th o d s  
Late-Stage C an cer Incidence
Data on new cases of invasive cancer diagnosed during 
2004—2006 were obtained from population-based cancer reg­
istries affiliated with C D C ’s N PC R  and N C I’s SEER program. 
Combined, these programs cover all o f the U.S. population 
and provide the best source of information on population- 
based cancer incidence for the nation. All participating cancer 
registries are members of the N orth American Association of 
Central Cancer Registries (NAACCR), a professional orga­
nization that establishes uniform data standards for cancer 
registration, trains cancer registry personnel, and certifies popu­
lation-based cancer registries. C D C  and N CI, in collaboration 
with NAACCR, maintain the U.S. Cancer Statistics (USCS) 
website, which contains the official federal statistics on cancer 
incidence from each registry that met data-quality criteria (29). 
Cancer registries demonstrated that cancer incidence data were 
of high quality by meeting six USCS publication criteria (29): 
1) case ascertainment is >90% complete, 2) <5% of cases are 
ascertained solely on the basis of a death certificate, 3) <3% 
of cases are missing information on sex, 4) <3% of cases are 
missing information on age, 5) <5% of cases are missing infor­
mation on race, and 6) >97% of the registry’s records passed a 
set of single-field and inter-field computerized edits that test 
the validity and logic of data components. C D C  analyzed data 
reported to N PC R  as of January 31, 2009, and data reported 
to SEER as of November 2008. A total of 49 registries that met 
the data-quality criteria for every year during 2004—2006 were 
included in this analysis. These registries cover approximately 
96% of the U.S. population, including 96% of the U.S. white 
population, 99% of the U.S. black population, 89% of the 
U.S. AI/AN population, 98% of the U.S. API population, and 
96% of the U.S. Hispanic population.
Sites for incident cancers were coded according to the 
International Classification of Diseases (ICD) for Oncology 
(ICD-O) edition in use at the time o f diagnosis, converted 
to the third edition coding (30): colon and rectum (C18—20, 
26.0), breast (C50), and cervix (C53). Clinical and pathologic 
tumor characteristics such as size, multiplicity, depth of inva­
sion and extension to regional or distant tissues, involvement 
of regional lymph nodes, and distant metastases were collected 
and classified using Collaborative Stage, a system used routinely 
by cancer registries (31). Collaborative Stage is used to derive 
three different staging systems, including SEER Summary Stage 
2000, which characterizes cancers as localized, regional, distant, 
or unknown stage (31). Late-stage cancers include regional or 
distant stage. SEER Summary Stage is used to indicate prog­
nosis, compare temporal trends, measure the success of cancer 
control efforts, and evaluate screening programs (31).
Population estimates used in the SEER*Stat software (avail­
able at http://seer.cancer.gov/seerstat) were a modified version 
of the annual time series of July 1 county population estimates 
by age, sex, and race/ethnicity produced by the U.S. Census 
Bureau (32). Modifications incorporated bridged single-race 
estimates that were derived from multiple-race categories in 
the 2000 Census (33). For most states, population estimates as 
of July 1 o f each year were used to calculate annual incidence 
rates because these estimates are presumed to reflect the average 
population of a defined geographic area for a calendar year. 
However, certain county population estimates were adjusted 
to account for populations displaced along the G ulf Coast of 
Louisiana, Alabama, Mississippi, and Texas in fall 2005 by 
hurricanes Katrina and Rita (32). National total population 
estimates were not affected by these adjustments. Other specific 
modifications included using additional local information 
to estimate the native Hawaiian population accurately and 
to derive population estimates for a newly created county in 
Colorado (32). The modified county-level population esti­
mates, summed to the state and national level, were used as 
denominators in rate calculations (32).
Average annual incidence rates per 100,000 persons were 
age-adjusted to the 2000 U.S. standard population by the direct 
method (34). Incidence rates were limited to age >50 years 
for colorectal and breast cancer and age >20 years for cervical 
cancer. Incidence rates were calculated for all races and ethnici­
ties combined and for each of five major racial/ethnic popula­
tions (white, black, AI/AN, API, and Hispanic). Information 
regarding race and Hispanic ethnicity were collected separately. 
Hispanic ethnicity includes men and women from all race 
categories identified as Hispanic. Cancer registry data for AI/ 
AN cases were linked with Indian Health Service (IHS) enroll­
ment records to decrease the number of AI/AN persons who 
were misclassified as nonnative (35). The NAACCR Hispanic
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Identification Algorithm was applied to Hispanic ethnicity 
data to reduce misclassification of Hispanic persons as being 
of unknown ethnicity (36). Late-stage incidence rates were 
examined by age, race/ethnicity, and state. Corresponding 
95% confidence intervals (CIs) were calculated as modified 
gamma intervals (37) and are presented to allow for compari­
sons among rates (38). For stability and reliability, rates were 
not reported if the numerator was fewer than 16 observations. 
All rate calculations were performed using SEER*Stat. Figures 
depict the geographic variability of age-adjusted incidence rates 
of late-stage cancer and percentage of cancers diagnosed at late 
stage by state, using quintiles as cutpoints.
C an cer Screening P revalence
In 2008, BRFSS was conducted in all 50 states, the District of 
Columbia, Puerto Rico, Guam, and the U.S. Virgin Islands (28). 
BRFSS uses a multistage sampling design based on random- 
digit-dialing methods to select a representative sample from the 
non-institutionalized adult population aged >18 years in each 
state and territory. Details on methodology, random sampling 
procedures, design, and reliability and validity of measures used 
in BRFSS have been described previously (39,40). According to 
the Council of American Survey and Research Organizations 
guidelines, the median 2008 BRFSS cooperation rate (the 
proportion of all respondents interviewed of all eligible units 
in which a respondent was selected and actually contacted) was 
75% and ranged from 59% to 88% among states (41). Questions 
on screening tests for colorectal, breast and cervical cancer were 
included in the core questionnaire in 2008 (42). Adult respon­
dents were asked a series of questions about colorectal cancer 
screening including whether they had ever used a FOBT and if 
so, how long it had been since their most recent test and whether 
they had ever had a sigmoidoscopy or colonoscopy and if so, 
which procedure it was and how long it had been since their 
most recent exam. Recommended colorectal cancer screening 
was defined as having had a FOBT in the preceding year, a flex­
ible sigmoidoscopy in the preceding 5 years, or a colonoscopy 
in the preceding 10 years. Adult female respondents were asked 
whether they had ever had a mammogram and how long it had 
been since their most recent mammogram. Current recom­
mended breast cancer screening was defined as having had a 
mammogram in the preceding 2 years. Adult female respondents 
were asked whether they had ever had a Pap test and how long it 
had been since their most recent Pap test. Current recommended 
cervical cancer screening was defined as having had a Pap test 
in the preceding 3 years. Populations were restricted to the ages 
recommended for screening by USPSTF: ages 50—75 years for 
colorectal cancer screening, ages 50—74 years for breast cancer 
screening, and ages 21—64 years for cervical cancer screening.
Percentages and exact CIs were weighted to the age, sex, racial, 
and ethnic distribution of the state’s adult population accord­
ing to the sampling design and age-adjusted to the 2000 U.S. 
standard population. Figures depict the geographic variability 
of age-adjusted estimated prevalence of cancer screening by state 
using quintiles as cutpoints.
R e su lts  
Colon a n d  Rectum C ancer
During 2004—2006, a total of 99,205 late-stage colon and 
rectum cancer cases (rate: 94.2 per 100,000 men) were diagnosed 
in men aged >50 years in the United States (Table 1). Incidence 
rates increased with increasing age, from 40.9 among men aged 
50—59 years to 182.9 among men aged >80 years. Incidence 
rates were highest among black men (114.0), followed by white 
(92.6), Hispanic (85.1), API (72.1), and AI/AN men (59.9). 
Incidence rates were lowest among AI/AN men aged 50—59 
years (30.7) and highest among black men aged >80 years
(192.9). State-specific late-stage colon and rectum incidence 
rates ranged from 67.5 to 125.1 and were highest in Alaska, 
Delaware, Illinois, Iowa, Kentucky, Louisiana, Nebraska, New 
Jersey, North Dakota, and Pennsylvania (range: 105.0—125.1) 
(Figure 1). Among all men, approximately half of colon and rec­
tum cancers were late-stage (Table 1). This percentage decreased 
with increasing age, from 53.8% among men aged 50—59 years 
to 46.6% among men aged >80 years, primarily as a result of 
an increase in the number of unstaged cancers (rather than as 
a result of an increase in the number of localized cancers). The 
percentage of late-stage cancers was lowest for white men. AI/AN 
men aged 50—59 years had the highest percentage of late-stage 
cancers (61.5%). The percentage of late-stage cancers varied by 
state (range: 43%—57%) (Figure 2).
Overall, 61.9% of men aged 50—75 years reported recom­
mended colorectal cancer screening in 2008 (Table 2). This 
percentage was lower for men aged 50—59 years (52.6%) 
and for men who were AI/AN (53.0%), API (50.7%), and 
Hispanic (46.5%). The percentage of men in each state who 
reported receiving recommended colorectal cancer screening 
varied (range: 51.3%—74.7%) (Figure 3) and was highest in 
Connecticut, Delaware, the District o f Columbia, Maine, 
Maryland, Massachusetts, Michigan, New Hampshire, Rhode 
Island, and Vermont (range: 66.2%—74.7%).
During 2004—2006, a total of 97,588 late-stage colon and 
rectum cancer cases (rate: 70.4 per 100,000 women) were diag­
nosed in women aged >50 years in the United States (Table 3). 
Incidence rates increased with increasing age, from 30.4 among 
women aged 50—59 years to 150.6 among women aged >80 
years. Incidence rates were highest among black women (85.6),
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followed by white (68.6), Hispanic (60.2), API (57.2), and 
AI/AN (48.9) women. Incidence rates were lowest in AI/AN 
women aged 50—59 years (24.0) and highest among white 
women aged >80 years (151.0). Among states, late-stage colon 
and rectum incidence rates varied (range: 51.0—86.5) and were 
highest in Connecticut, Delaware, Illinois, Iowa, Kentucky, 
Louisiana, Maine, Nebraska, New Jersey, and Pennsylvania 
(range: 74.7-86.5) (Figure 4). Among all women, approxi­
mately half of colon and rectum cancers were late-stage (Table 
3). This percentage decreased with increasing age, from 54.1% 
among women aged 50-59 years to 47.7% among women aged 
>80 years, as a result of an increase in the number of localized 
cancers up to age 79 years and an increase in the number of 
unstaged cancers in persons aged >80 years. The percentage of 
late-stage cancers was lowest (50.9%) for white women. AI/ 
AN women aged 50-59 years had the highest percentage of 
late-stage cancers (60.5%). The percentage oflate-stage cancers 
varied by state (range: 45% —58%) (Figure 5).
Overall, 62.0% of women aged 50-75 years reported recom­
mended colorectal cancer screening in 2008 (Table 4). This 
percentage was lower for women aged 50—59 years (53.6%) 
and for women who were AI/AN (53.9%), API (56.4%), 
and Hispanic (51.0%). The percentage o f women in each 
state who reported recommended colorectal cancer screening 
varied (range: 48.6% -72.5% ) (Figure 6) and was highest in 
Connecticut, Delaware, M aine, Maryland, Massachusetts, 
Minnesota, New Hampshire, Rhode Island, Vermont, and 
Virginia (range: 68.2% -72.5% ).
B reast C an cer
During 2004-2006, a total o f 147,430 late-stage breast 
cancer cases (rate: 108.5 cases per 100,000 women) were diag­
nosed in women aged >50 years in the United States (Table 5). 
Incidence rates were lowest among women aged 50—59 years
(93.0), highest among women aged 60—69 (119.2) and 70—79
(123.9) years, and intermediate among women aged >80 years 
(109.7). Incidence rates were highest among black women 
(124.3), followed by white (107.6), Hispanic (87.8), API
(67.1), and AI/AN (61.4) women. Incidence rates were lowest 
in AI/AN women aged 50—59 years (48.8) and highest among 
black women aged 70—79 years (140.5). Among states, late- 
stage breast cancer incidence rates ranged from 92.2 to 132.1 
and were highest in Alabama, the District of Columbia, Kansas, 
Louisiana, Mississippi, New Jersey, Oklahoma, Pennsylvania, 
Tennessee, and Washington (range: 115.0—132.1) (Figure 7). 
Among all women, approximately a third of breast cancers were 
late-stage (Table 5). This percentage decreased with increasing 
age, from 38.4% among women aged 50—59 years to 29.3% 
among women aged >80 years, because of an increase in the
number of localized cancers in women up to age 79 years and 
an increase in the number of unstaged cancers in women aged 
>80 years. The percentage of late-stage cancers was lowest for 
white women (32.7%) and highest for black women (42.4%). 
Black women aged 50—59 years had the highest percentage 
of late-stage cancers (46.4%). Among states, the percentage 
of breast cancers that were late-stage varied by state (range: 
27% -4 l% ) (Figure 8).
Overall, 81.2% of women aged 50—74 years reported receiv­
ing recommended breast cancer screening in 2008 (Table 6). 
This percentage was lower only for women who were AI/ 
AN (70.4%). The percentage of women in each state who 
reported receiving recommended breast cancer screening 
varied (range: 72.1%—89.8%) (Figure 9) and was highest in 
Connecticut, Delaware, the District of Columbia, Georgia, 
Maine, Massachusetts, Michigan, New Hampshire, New York, 
and Rhode Island (range: 83.9%—89.8%).
C ervica l C ancer
During 2004—2006, a total o f 16,947 late-stage cervi­
cal cancer cases (5.2 per 100,000 women) were diagnosed 
in women aged >20 years in the United States (Table 7). 
Incidence rates were lowest am ong wom en aged 20—29 
years (0.8), highest among women aged 50—79 years (range: 
7 .2-7.9), and intermediate among women aged 30—49 years 
or >80 years (4.1—6.3). Incidence rates were highest among 
Hispanic women (8.4), followed by black (7.8), API (5.2), 
white (4.9), and AI/AN (4.4) women. Incidence rates were 
lowest in white women aged 20—29 years (0.8) and highest 
among black women aged 70—79 years (15.1). Among states, 
late-stage cervical cancer incidence rates ranged from 3.0—8.3 
and were highest in Arkansas, the District of Columbia, Illinois, 
Kentucky, Louisiana, Mississippi, Nevada, New Mexico, and 
Oklahoma (6.1—8.3) (Figure 10). Among all women, 47% of 
cervical cancers were late-stage (Table 7). This percentage was 
lowest among women aged 20—29 years (23.1%). The per­
centage of late-stage cancers was lowest for Hispanic women 
(45.9%) and highest for black women (52.8%). Among states, 
this percentage varied (range: 34%—53%) (Figure 11).
Overall, 87.6% of women aged 21—64 years had recom­
mended cervical cancer screening in 2008 (Table 8). This per­
centage was lower for women who were aged >50 years (range: 
83.1-86.0%), AI/AN (82.9%), and API (80.3%). The percent­
age of women in each state who had recommended cervical 
cancer screening varied (range: 81.0% -92.6% ) (Figure 12) 
and was highest in Delaware, the District of Columbia, Maine, 
Massachusetts, Minnesota, New Hampshire, N orth Carolina, 
Rhode Island, Vermont, and Virginia (range: 90.3-92.6% ).
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D isc u ssio n  
Interpretation o f S creening-A m en ab le  
C an cer Incidence a n d  C ancer 
Screening P revalence
This report presents a snapshot of the situation in the United 
States using the most recent available estimates of late-stage 
cancer incidence (2004—2006) and screening prevalence 
(2008). During 2004—2006, approximately half of colorectal 
and cervical cancers and one third of breast cancers in the 
United States were diagnosed at a regional or distant stage, 
when treatment is not as effective and survival is worse com­
pared with cancers diagnosed at a localized stage.
Examining both the rate and percentage of late-stage cancer is 
useful. Rates measure absolute burden of disease, which is use­
ful for program planning. The rate of late-stage cancer provides 
some information about the overall (all stages combined) rate, 
the magnitude o f which reflects the impact of underlying risk 
factors. Percentages measure proportionate burden of disease, 
which is helpful in comparing rates on different scales, such 
as by age. The percentage o f late-stage cancer measures the 
proportion o f cancers not detected at earlier, more treatable 
stage of disease, i.e., cancers that might have been detected with 
timely and effective screening. A high percentage of late-stage 
cancer may indicate, among other factors, low population- 
based screening rates.
Black men and women tended to have both higher rates of 
late-stage cancers and higher percentage of late-stage cancers 
than other racial/ethnic groups. AI/AN, API, and Hispanic 
men and women had lower rates but higher percentage of late- 
stage colorectal and female breast cancer than whites. Hispanic 
women had the highest rate of late-stage cervical cancer but 
the lowest percentage diagnosed at late-stage. The percentage 
of late-stage breast and colorectal cancers decreased with age, 
probably reflecting patterns of increasing use of colorectal and 
breast cancer screening with age. In contrast, the percentage of 
late-stage cervical cancers increased with women’s age, which 
might reflect, in part, lower use of Pap tests.
The incidence rate and percentage of late-stage cancer varied 
by state. Unlike geographic patterns of heart disease and stroke 
incidence, which are highest in the South, mostly reflecting 
higher prevalence o f cigarette smoking and hypertension (43), 
geographic patterns differed for each cancer site, reflecting 
differing importance of underlying demographic characteris­
tics (e.g., age) and lifestyle behaviors (e.g., cigarette smoking, 
obesity, and screening use). Lifestyle behaviors that increase 
colorectal cancer risk include obesity, physical inactivity, exces­
sive alcohol consumption, a diet high in red or processed meat 
and cigarette smoking (8,23). Lifestyle behaviors that increase
breast cancer risk include being overweight or obese after 
menopause, using hormone replacement therapy, being physi­
cally inactive, and consuming more than one alcoholic drink a 
day (23). Lifestyle behaviors that increase cervical cancer risk 
include H PV  infection and cigarette smoking (23,24). The 
prevalence of these lifestyle behaviors vary by state (28).
Population-based screenings for colorectal, breast and cervi­
cal cancer are proven interventions for decreasing the incidence 
and mortality from these cancers (2—4). However, millions 
of adults in the United States do not receive recommended 
screening for colorectal cancer (16), breast cancer (20), or 
cervical cancer (26). In this report, only 62% of adults met 
recommended screening guidelines for colorectal cancer; this 
percentage varied from 49% to 75% among states. Hispanic, 
AI/AN, and API men and women were less likely to receive col­
orectal cancer screening than white or black men and women. 
In this report, 81% of adult women aged 50—74 years had a 
mammogram during the preceding 2 years; this percentage 
varied from 72% to 90% among states. Similar to other reports, 
the lowest prevalence was among AI/AN women (20). In this 
report, 88% of women aged >21—64 years had received a Pap 
test during the preceding 3 years; this percentage varied by age 
and race/ethnicity and from 81% to 93% by state.
Lim itations
The findings in this report are subject to at least five limi­
tations. First, although these cancer incidence data covered 
96% of the U.S. population and are the most inclusive study 
of the U.S. population, high-quality incidence data were not 
available from Arizona or Wisconsin. Second, data for AI/ 
ANs are underreported in cancer registries (44). Linkage 
with external sources of information such as IHS enrollment 
records improved the quality o f AI/AN data in this study (35); 
however, because IHS serves only federally recognized tribes, 
these data do not fully represent all AI/ANs, especially those in 
state-recognized tribes or those who do not seek care from IHS. 
Third, BRFSS collects self-reported use of screening tests that 
are not validated and respondents might not accurately recall 
the length of time since their most recent screening test and 
might either over-report or under-report the use of the screen­
ing test. In addition, respondents are not asked whether the 
test was used as a screening or diagnostic tool. Fourth, because 
BRFSS is a telephone survey of residential households, only 
adults in households with landline telephones are represented; 
therefore the results might not be representative of the U.S. 
population. Finally, the survey response rate was low, which 
increases the risk for response bias.
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Public Health Action
The findings in this report emphasize the need for ongoing 
population-based surveillance and reporting to monitor cancer 
incidence trends. Cancer-control planners, including compre­
hensive cancer-control programs, can use cancer incidence and 
screening prevalence data to identify populations that would 
benefit from targeted screening interventions to realize the 
maximum benefits of cancer screening. The geographic pattern 
of late-stage cancers vary by cancer type. High rates of late- 
stage incidence of screening-amenable cancers might reflect 
in part demographic patterns, the ineffectiveness of screening 
programs (e.g., not reaching enough of the population, not 
reaching those at highest risk, or technical problems with the 
screening tests), or problems with quality of follow-up for 
abnormal screening test results. States might find it helpful to 
compare their demographic data with the national data pre­
sented in this report or with data from other states to determine 
the extent to which these factors might play a role.
Screening for colorectal, breast, and cervical cancer can 
identify cancer in earlier and more treatable stages o f disease. 
Multiple factors, including individual characteristics and health 
behaviors as well as provider and clinical systems factors, influ­
ence why certain populations are underscreened. Identifying 
which men and women do not receive recommended screen­
ing is an im portant step in reducing cancer mortality. For 
example, screening rates are lower for men and women with 
low income, without health insurance, and without access to 
care and vary by age, education, race/ethnicity, and recent 
immigration (45). Even among men and women with health 
insurance, 34% had not received a FOBT during the preceding 
year or a lower endoscopy during the preceding 10 years (16), 
and 16% of women had not received mammography during 
the preceding 2 years (20). Social and economic disparities, 
lack o f awareness of the need for screening, lack of physician 
recommendation, and lack of insurance coverage, are major 
factors in the underuse of cancer screening (15,26,46).
Screening rates also differ by type of cancer. This variation 
may be due to factors previously discussed as well as the length 
of time since the test was first developed and used as a screen­
ing tool, recommendation of the test as a clinical preventive 
service, and inclusion of the test as a health insurance benefit. 
M andated health insurance coverage of screening tests vary by 
state (21). Screening rates are highest for the Pap test (88% in 
this report) which was introduced in the 1940s and quickly 
integrated into routine clinical practice (22). Screening rates 
for mammography (81% in this report) nearly doubled from 
1987 to 1992; USPSTF guidelines were published in 1989 
and private insurance coverage and Medicare benefits were 
mandated shortly after (17,45). Screening rates are lowest for
colorectal cancer screening (62% in this report), tests for which 
were developed and recommended later than those for breast 
and cervical cancer screening (2,8). Screening rates seem to 
have plateaued for cervical and breast cancer screening (26) but 
are increasing steadily for colorectal cancer screening (16).
The U.S. Task Force on Com m unity Preventive Services 
identified three prim ary strategies to increase screening 
rates: increasing community demand (47), increasing com­
m unity access (48), and increasing provider delivery (49). 
The Community Guide recommended interventions such as 
patient reminder systems, small media (e.g., videos, letters, 
flyers, and brochures), one-on-one provider interactions, 
reducing structural barriers (e.g., providing more convenient 
hours and increasing attention to language, health literacy, 
and cultural factors), reducing financial barriers, and use of 
provider assessment and feedback to increase screening (50). 
These recommendations are echoed in the 2010 National 
Institute o f Health panel on enhancing use and quality of 
colorectal cancer screening, which advised the elimination of 
financial barriers and implementation of proven interventions 
such as patient reminder systems and one-on-one provider 
interactions (51).
One program that is using these recommended strategies 
successfully to improve access to breast and cervical cancer 
screening and diagnostic services is the National Breast and 
Cervical Cancer Early Detection Program (NBCCEDP). 
NBCCEDP has provided these services to low-income, unin­
sured, and underinsured women for the preceding 20 years
(52) and is the only national organized screening program 
in the United States. The program provides free or low-cost 
mammography and Pap tests to women with low income or 
without adequate health insurance in all 50 states, the District 
of Columbia, 12 tribes and tribal organizations, and five U.S. 
territories. NBCCED P has program standards for timeliness 
and completeness of follow-up for abnormal screening tests 
and treatment initiation after precancer or cancer diagnosis. 
Funded programs are required to collect data on screening 
test characteristics and follow-up for all women who receive 
services paid for by the program. A recent study examining 
the timeliness and completeness o f follow-up showed that the 
majority of women screened by NBCCEDP received appropri­
ate and timely diagnostic follow-up and initiated treatment
(53). An estimated 8%—11 % o f U.S. women o f screening 
age are eligible to receive NBCCED P services; approximately 
14.3% o f eligible women are screened for breast cancer (52), 
and 9% are screened for cervical cancer (54). Many states have 
augmented these federal funds to expand the population of 
uninsured women that they can reach (55); however, recent 
economic constraints on state, tribal, and territorial program 
funding have resulted in reduced services (56,57).
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A program that emphasizes population-based approaches to 
increase screening is the Colorectal Cancer Control Program 
established recently by the C D C  (58). This program provides 
funding to 25 states and four tribal organizations to promote 
colorectal cancer screening using evidence-based strategies 
recommended by the Task Force on Community Preventive 
Services and to provide colorectal cancer screening and follow- 
up care to low-income men and women aged 50—64 years who 
are underinsured or uninsured for screening (59).
The potential benefit o f screening is realized only when 
it results in a timely diagnosis o f disease that then is treated 
effectively (60). Quality of follow-up of abnormal screening 
tests is recognized increasingly as an important aspect o f can­
cer screening (61). Patients with low income or who belong 
to certain racial/ethnic groups have longer delays in receiving 
appropriate diagnostic and treatment services following an 
abnormal screening test; however, many of these disparities can 
be explained by differences in health-care use and health-care 
setting, as well as by lack of adequate health insurance (62—65). 
Facilitating cancer screening (66) should be a focus of emerging 
practice-based quality-improvement demonstration systems 
such as the patient-centered medical home (67). Screening 
registries, such as the Breast Cancer Surveillance Consortium
(68), can be used to track the screening process and moni­
tor the quality, timeliness, and completeness of follow-up of 
abnormal screening tests as well as entry into treatment services
(69). To address disparities in the receipt o f timely and quality 
diagnostic services, programs that offer services such as case 
management or patient navigation to assist persons in accessing 
follow-up and treatment appear promising (70,71).
After determining the extent to which factors might affect 
the incidence of late-stage diagnoses and screening rates, States 
might find it helpful to determine the next steps for appropriate 
interventions. Comprehensive cancer control is an integrated 
and coordinated approach for reducing the burden of cancer 
incidence, morbidity, and mortality through a continuum of 
services including prevention, early detection, treatment, sur­
vivorship, and palliation (72). A key part of this is promoting 
recommended cancer screening guidelines using culturally-sen- 
sitive interventions and ensuring that evidence-based screening 
tests and treatments are available and accessible. Because this 
is accomplished most effectively at the local and state level, 
C D C ’s National Comprehensive Cancer Control Program (72) 
provides financial support and technical assistance to all 50 
states, the District of Columbia, seven tribes and tribal orga­
nizations, and seven U.S. Associated Pacific Islands/territories 
to develop and implement a coordinated cancer-control plan. 
Cancer-control planners can use several online resources to 
discover the source of disparities in cancer incidence and cancer 
screening and to identify the most effective, evidence-based
interventions to increase screening adherence. Cancer Control 
PL.A.N.E.T. (Plan, Link, Act, Network with Evidence-based 
Tools) (http://cancercontrolplanet.cancer.gov) provides tools 
to assess the cancer and/or risk factor burden within a state, 
identify potential partners, understand research findings and 
recommendations, access evidence-based programs and prod­
ucts, and find guidelines for planning and evaluation. State 
Cancer Profiles (http://statecancerprofiles.cancer.gov/index. 
htm l) integrates surveillance into cancer control planning by 
characterizing the cancer and risk factor burden in geographic 
and demographic groups. U.S. Cancer Statistics (http://apps. 
nccd.cdc.gov/uscs/) presents high-quality cancer incidence 
and mortality statistics for the United States for 1999—2006. 
The Guide to Com munity Preventive Services (http://www. 
thecommunityguide.org/cancer/index.html) summarizes the 
effectiveness of population-based interventions so that cancer­
control planners can choose the programs and policies that are 
right for their communities.
H ealth C a re  Reform
O n March 23, 2010, the Patient Protection and Affordable 
Care Act (P.L. 111—148) became law (73). This act requires 
private health insurers and Medicare to cover recommended 
clinical preventive services graded “A” or “B” by USPSTF, 
including the screening tests described in this report, at no 
cost to insured patients (74). In addition, private insurers will 
be required to provide mammograms at no cost to women 
aged >40 years. This law expands the Medicaid state option 
to provide clinical preventive services recommended with a 
rating of “A” or “B” by USPSTF and increases the federal 
medical assistance percentage (FMAP) by one percentage 
point in states that eliminate cost sharing for these services. In 
addition, the law substantially expands Medicaid eligibility to 
persons, including nonpregnant childless adults, with incomes 
<133% of the federal poverty level (FPL) and optional coverage 
for those with incomes >133% of FPL. The law also expands 
private insurance coverage through employer mandates and tax 
credits for health insurance benefits and subsidies for persons 
to purchase insurance through state-based exchanges.
Ensuring coverage of recommended cancer screening, in part 
by removing financial barriers, is a critical first step in increas­
ing the number of persons in the United States who receive 
these services. An important next step is ensuring appropriate 
and timely follow-up o f abnormal screening tests (71) which 
requires a systematic approach to follow-up and surveillance 
(75). Systematic screening programs have been implemented in 
some managed care settings (76) and in programs such as the 
NBCCED P (52) and the Colorectal Cancer Control Program 
(58) and could be applied across the U.S. population. The
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development o f population-based registries o f persons eligible 
for screening, for example, the Breast Cancer Surveillance 
Consortium (69), would help define the population eligible 
for screening and identify opportunities for targeted outreach 
to disparate populations. By working collaboratively, public 
health authorities can prom ote quality improvement and 
systems change interventions to assure evidence-based screen­
ing practice in clinical settings. The complexity of adequate 
follow-up testing after abnormal screening tests underscores the 
importance of public health authorities continuing to facili­
tate and ensure appropriate diagnostic testing and treatment 
thorough surveillance and case management o f those persons 
who screen positive.
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FIGURE 1. Rate* of late-stage colorectal cancer among men aged FIGURE 2. Percentage of colorectal cancers diagnosed at late stage











K3 Area did not meet 
data-quality criteria
Source: CDC's National Program of Cancer Registries (NPCR) and the National 
Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard population. 
f Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria 
for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
Source: CDC's National Program of Cancer Registries (NPCR) and the National 
Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria 
for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
FIGURE 3. Percentage of men aged 50-75 years who had recommended 
colorectal cancer screening* —  Behavioral Risk Factor Surveillance 
System, United States, 2008
* Determined by having met the U.S. Preventive Services Task Force recommenda­
tion of having a fecal occult blood test in the past year, a flexible sigmoidoscopy 
in the past 5 years, or a colonoscopy in the preceding 10 years (14).
FIGURE 4. Rate* of late-stage colorectal cancer among women aged >50 
years —  United States,1 2004-2006
Source: CDC's National Program of Cancer Registries (NPCR) and the National 
Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard population. 
f Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria 
for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
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FIGURE 5. Percentage of colorectal cancers diagnosed at late stage 
among women aged >50 years —  United States,* 2004-2006
Source: CDC's National Program of Cancer Registries (NPCR) and the National 
Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria 
for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
FIGURE 7. Rate* of late-stage invasive female breast cancer among 
women aged >50 years —  United States,1 2004-2006
Source: CDC's National Program of Cancer Registries (NPCR) and the National 
Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard population. 
f Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria 
for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
FIGURE 6. Percentage of women aged 50-75 years who had 
recommended colorectal cancer screening* —  Behavioral Risk 
Factor Surveillance System, United States, 2008
* Determined by having met the U.S. Preventive Services Task Force recommenda­
tion of having a fecal occult blood test in the past year, a flexible sigmoidoscopy 
in the past 5 years, or a colonoscopy in the preceding 10 years (14).
FIGURE 8. Percentage of breast cancers diagnosed at late stage 





Area did not meet 
data-quality criteria
Source: CDC's National Program of Cancer Registries (NPCR) and the National 
Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria 











^  Area did not meet 
data-quality criteria
Vol. 59  /  SS-9 Surveillance Sum m aries 13
FIGURE 9. Percentage of women aged 50-74 years who had recom­
mended breast cancer screening* —  Behavioral Risk Factor Surveil­
lance System, United States, 2008
* Determined by having met the U.S. Preventive Services Task Force recom­
mendation of having had a mammogram in the preceding 2 years (19).
FIGURE 10. Rate* of late-stage invasive cervical cancer among 
women aged >20 years —  United States,1 2004-2006
Source: CDC's National Program of Cancer Registries (NPCR) and the National 
Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard population. 
f Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria 
for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
FIGURE 11. Percentage of cervical cancers diagnosed at late stage 
among women aged >20 years —  United States,* 2004-2006
Source: CDC's National Program of Cancer Registries (NPCR) and the National 
Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria 
for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
FIGURE 12. Percentage of women aged 21-64 years who had 
recommended cervical cancer screening* —  Behavioral Risk Factor 
Surveillance System, United States, 2008
* Determined by having met the U.S. Preventive Services Task Force recom­
mendation of having had a Pap test in the preceding 3 years (25).
14 M M W R N ovem b er 26, 20 10
TABLE 1. Invasive colorectal cancer incidence,* men aged >50 years, by stage, age, and race/ethnicity —  United States,1 2004-2006
Age group at diagnosis (yrs)
Overall Late (Regional + Distant)5
No. Rate (95% CI) No. Rate (95% CI) %
All races/ethnicities
>50 196,476 188.3 (187.5-189.2) 99,205 94.2 (93.6-94.8) 50.5
50-59 40,296 76.0 (75.3-76.7) 21,680 40.9 (40.3-41.4) 53.8
60-69 54,018 174.3 (172.8-175.8) 28,321 91.3 (90.2-92.3) 52.4
70-79 59,889 301.6 (299.2-304.0) 29,510 148.6 (146.9-150.3) 49.3
>80 42,273 393.9 (390.2-397.7) 19,694 182.9 (180.3-185.5) 46.6
White
>50 168,442 185.4 (184.5-186.3) 84,770 92.6 (91.9-93.2) 50.3
50-59 32,584 72.7 (71.9-73.5) 17,572 39.2 (38.6-39.7) 53.9
60-69 45,383 169.9 (168.3-171.4) 23,737 88.7 (87.6-89.9) 52.3
70-79 52,397 299.1 (296.5-301.7) 25,790 147.2 (145.4-149.0) 49.2
>80 38,078 395.1 (391.2-399.1) 17,671 182.7 (180.0-185.5) 46.4
Black
>50 19,977 217.0 (213.9-220.2) 10,677 114.0 (111.7-116.3) 53.5
50-59 5,551 100.4 (97.8-103.1) 3,109 56.2 (54.3-58.3) 56.0
60-69 6,199 218.3 (212.9-223.8) 3,424 120.2 (116.2-124.4) 55.2
70-79 5,294 334.4 (325.4-343.6) 2,710 170.7 (164.3-177.3) 51.2
>80 2,933 396.1 (381.9-410.7) 1,434 192.9 (183.0-203.2) 48.9
American Indian/Alaska Native
>50 782 117.9 (109.2-127.2) 414 59.9 (53.8-66.5) 52.9
50-59 218 49.8 (43.4-56.9) 134 30.7 (25.7-36.3) 61.5
60-69 270 124.0 (109.6-139.8) 142 64.2 (54.0-75.8) 52.6
70-79 195 183.5 (158.5-211.3) 89 83.6 (67.0-103.0) 45.6
>80 99 216.2 (175.6-263.5) 49 106.3 (78.6-140.8) 49.5
Asian/Pacific Islander
>50 5,046 135.1 (131.3-139.1) 2,710 72.1 (69.3-75.0) 53.7
50-59 1,268 57.0 (53.9-60.3) 698 31.4 (29.1-33.8) 55.0
60-69 1,531 126.6 (120.3-133.1) 824 68.1 (63.6-73.0) 53.8
70-79 1,403 214.5 (203.4-226.1) 741 113.0 (105.0-121.4) 52.8
>80 844 274.4 (256.1-293.6) 447 144.7 (131.6-158.8) 53.0
Hispanic
>50 11,721 163.2 (160.1-166.4) 6,222 85.1 (82.9-87.4) 53.1
50-59 3,080 67.5 (65.1-69.9) 1,675 36.7 (35.0-38.5) 54.4
60-69 3,531 156.6 (151.5-161.9) 1,975 87.5 (83.7-91.4) 55.9
70-79 3,347 267.6 (258.6-276.8) 1,760 140.8 (134.2-147.5) 52.6
>80 1,763 313.1 (298.5-328.1) 812 143.5 (133.8-153.8) 46.1
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TABLE 1. (Continued) Invasive colorectal cancer incidence,* men aged >50 years, by stage, age, and race/ethnicity —  United States,1 2004-2006
Age group at diagnosis (yrs)
Localized5 Regional5 Distant5 Unstaged
No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI)
All races/ethnicities (continued)
>50 80,911 77.7 (77.1-78.2) 64,655 61.7 (61.2-62.2) 34,550 32.5 (32.2-32.8) 16,356 16.4 (16.2-16.7)
50-59 16,078 30.3 (29.9-30.8) 13,499 25.5 (25.0-25.9) 8,181 15.4 (15.1-15.8) 2,538 4.8 (4.6-5.0)
60-69 22,159 71.6 (70.7-72.6) 18,114 58.4 (57.6-59.3) 10,207 32.8 (32.2-33.5) 3,537 11.4 (11.0-11.8)
70-79 25,777 129.8 (128.2-131.4) 19,711 99.3 (97.9-100.7) 9,799 49.3 (48.3-50.3) 4,600 23.2 (22.5-23.9)
>80 16,897 156.8 (154.5-159.2) 13,331 123.7 (121.6-125.8) 6,363 59.2 (57.7-60.6) 5,681 54.2 (52.8-55.6)
White
>50 70,150 77.3 (76.8-77.9) 55,896 61.3 (60.8-61.8) 28,874 31.3 (30.9-31.6) 13,522 15.5 (15.3-15.8)
50-59 13,093 29.2 (28.7-29.7) 11,091 24.7 (24.3-25.2) 6,481 14.4 (14.1-14.8) 1,919 4.3 (4.1-4.5)
60-69 18,849 70.7 (69.7-71.7) 15,377 57.6 (56.6-58.5) 8,360 31.2 (30.5-31.9) 2,797 10.5 (10.1-10.9)
70-79 22,775 130.0 (128.3-131.7) 17,372 99.2 (97.7-100.7) 8,418 48.0 (47.0-49.1) 3,832 21.9 (21.2-22.6)
>80 15,433 159.5 (157.0-162.1) 12,056 124.6 (122.4-126.8) 5,615 58.2 (56.7-59.7) 4,974 52.9 (51.4-54.4)
Black
>50 7,364 79.9 (78.0-81.8) 6,282 67.6 (65.9-69.4) 4,395 46.4 (45.0-47.9) 1,932 23.1 (22.0-24.2)
50-59 2,028 36.7 (35.1-38.3) 1,768 32.0 (30.5-33.5) 1,341 24.3 (23.0-25.6) 414 7.5 (6.8-8.2)
60-69 2,288 80.8 (77.6-84.2) 1,998 70.3 (67.2-73.4) 1,426 50.0 (47.4-52.7) 486 17.1 (15.7-18.7)
70-79 2,051 129.6 (124.0-135.3) 1,647 103.6 (98.6-108.8) 1,063 67.1 (63.1-71.3) 531 34.0 (31.2-37.1)
>80 997 134.2 (126.0-142.8) 869 117.0 (109.3-125.1) 565 75.9 (69.7-82.4) 501 68.9 (63.0-75.2)
American Indian/Alaska Native
>50 288 44.3 (39.0-50.2) 246 36.4 (31.7-41.7) 168 23.5 (19.8-27.7) 80 13.7 (10.7-17.3)
50-59 68 15.5 (12.1-19.7) 78 17.8 (14.1-22.3) 56 12.8 (9.7-16.7) 16 3.6 (2.1-5.9)
60-69 104 48.5 (39.6-58.8) 79 35.6 (28.1-44.4) 63 28.6 (21.9-36.6) 24 11.3 (7.2-16.8)
70-79 85 80.3 (64.1-99.5) 58 55.2 (41.8-71.4) 31 28.4 (19.3-40.4) 21 19.6 (12.1-30.1)
>80 31 67.8 (46.0-96.5) 31 67.1 (45.5-95.4) 18 39.2 (23.2-62.2) 19 42.1 (25.3-65.8)
Asian/Pacific Islander
>50 2,022 53.8 (51.4-56.3) 1,797 48.3 (46.0-50.7) 913 23.8 (22.3-25.5) 314 9.2 (8.2-10.3)
50-59 515 23.2 (21.2-25.3) 447 20.1 (18.3-22.0) 251 11.3 (9.9-12.8) 55 2.5 (1.9-3.2)
60-69 617 51.0 (47.1-55.2) 538 44.5 (40.8-48.5) 286 23.6 (20.9-26.5) 90 7.4 (6.0-9.1)
70-79 584 89.5 (82.4-97.1) 498 76.1 (69.5-83.1) 243 36.9 (32.4-41.9) 78 12.0 (9.5-15.0)
>80 306 99.1 (88.3-110.9) 314 101.5 (90.5-113.4) 133 43.2 (36.2-51.3) 91 30.5 (24.6-37.5)
Hispanic
>50 4,481 62.6 (60.7-64.6) 4,054 55.9 (54.1-57.7) 2,168 29.3 (28.0-30.6) 1,018 15.5 (14.5-16.5)
50-59 1,168 25.6 (24.1-27.1) 1,072 23.5 (22.1-24.9) 603 13.2 (12.2-14.3) 237 5.2 (4.6-5.9)
60-69 1,318 58.6 (55.4-61.8) 1,279 56.7 (53.6-59.9) 696 30.8 (28.5-33.1) 238 10.6 (9.3-12.0)
70-79 1,317 105.2 (99.6-111.1) 1,144 91.8 (86.5-97.3) 616 49.0 (45.2-53.0) 270 21.6 (19.1-24.4)
>80 678 119.9 (111.0-129.4) 559 98.9 (90.8-107.5) 253 44.6 (39.3-50.5) 273 49.6 (43.9-55.9)
Abbreviation: CI = confidence interval.
Source: CDC's National Program of Cancer Registries (NPCR) and the National Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard population; 95% confidence intervals were calculated as modified gamma intervals (37). 
f Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
§ A localized cancer is one that is confined to the primary site, a regional cancer is one that has spread directly beyond the primary site or to regional lymph nodes, 
and a distant cancer is one that has spread to other organs.
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TABLE 2. Number and percentage of men who received recom­
mended colorectal cancer screening* —  Behavioral Risk Factor 
Surveillance System, United States, 2008
Men
Demographic No. % (95% CI)
Overall 71,456 61.9 (61.3-62.6)
Age at screening (yrs)
50-59 33,226 52.6 (51.6-53.6)
60-69 28,753 71.3 (70.3-72.2)
70-75 10,109 75.5 (73.9-76.9)
Race
White 63,442 63.1 (62.4-63.8)
Black 4,328 62.0 (59.3-64.5)
American Indian/Alaska Native 1,145 53.0 (47.0-59.0)
Asian/Pacific Islander 1,156 50.7 (44.9-56.4)
Ethnicity
Hispanic 2,607 46.5 (42.9-50.1)
Non-Hispanic 69,122 63.4 (62.7-64.0)
Abbreviation: CI = confidence interval.
* Determined by having met the U.S. Preventive Services Task Force recom­
mendation of having a fecal occult blood test in the preceding year, a flexible 
sigmoidoscopy in the preceding 5 years or a colonoscopy in the preceding 10 
years (14).
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TABLE 3. Invasive colorectal cancer incidence* among women aged >50 years, by stage, age, and race/ethnicity —  United States,1 2004-2006
Age group at diagnosis (yrs)
Overall Late (Regional + Distant)5
No. Rate (95% CI) No. Rate (95% CI) %
All races/ethnicities
>50 191,283 137.3 (136.7-137.9) 97,588 70.4 (69.9-70.8) 51.0
50-59 31,344 56.2 (55.6-56.9) 16,968 30.4 (30.0-30.9) 54.1
60-69 40,625 116.6 (115.5-117.8) 21,838 62.6 (61.8-63.5) 53.8
70-79 56,139 215.4 (213.6-217.2) 28,664 110.0 (108.7-111.3) 51.1
>80 63,175 315.0 (312.5-317.4) 30,118 150.6 (148.9-152.4) 47.7
White
>50 161,416 133.8 (133.1-134.4) 82,193 68.6 (68.1-69.0) 50.9
50-59 23,910 51.9 (51.2-52.5) 13,097 28.4 (27.9-28.9) 54.8
60-69 32,916 111.8 (110.6-113.0) 17,693 60.0 (59.1-60.9) 53.8
70-79 47,971 212.5 (210.6-214.5) 24,442 108.4 (107.0-109.7) 51.0
>80 56,619 316.0 (313.4-318.6) 26,961 151.0 (149.2-152.8) 47.6
Black
>50 22,144 162.5 (160.4-164.7) 11,690 85.6 (84.1-87.2) 52.8
50-59 5,490 82.7 (80.6-85.0) 2,990 45.0 (43.4-46.7) 54.5
60-69 5,800 154.8 (150.8-158.8) 3,186 85.0 (82.0-88.0) 54.9
70-79 5,976 241.1 (235.0-247.3) 3,159 127.4 (123.0-132.0) 52.9
>80 4,878 307.0 (298.4-315.7) 2,355 148.6 (142.6-154.7) 48.3
American Indian/Alaska Native
>50 713 90.5 (83.8-97.7) 392 48.9 (44.1-54.2) 55.0
50-59 185 39.7 (34.2-45.9) 112 24.0 (19.8-28.9) 60.5
60-69 197 83.3 (72.0-95.8) 110 46.5 (38.1-56.0) 55.8
70-79 208 158.5 (137.6-181.6) 105 80.2 (65.5-97.1) 50.5
>80 123 156.1 (129.6-186.3) 65 82.5 (63.6-105.2) 52.8
Asian/Pacific Islander
>50 4,966 104.3 (101.4-107.3) 2,726 57.2 (55.0-59.4) 54.9
50-59 1,222 47.7 (45.1-50.5) 653 25.4 (23.5-27.4) 53.4
60-69 1,241 89.1 (84.2-94.2) 714 51.2 (47.5-55.1) 57.5
70-79 1,416 158.2 (150.1-166.7) 775 86.5 (80.5-92.8) 54.7
>80 1,087 231.5 (218.0-245.7) 584 124.2 (114.3-134.7) 53.7
Hispanic
>50 10,047 110.8 (108.6-113.0) 5,504 60.2 (58.6-61.8) 54.8
50-59 2,342 49.2 (47.3-51.3) 1,378 29.0 (27.5-30.5) 58.8
60-69 2,645 99.9 (96.2-103.8) 1,474 55.6 (52.8-58.5) 55.7
70-79 2,828 169.1 (162.9-175.4) 1,524 91.1 (86.6-95.8) 53.9
>80 2,232 236.9 (227.2-247.0) 1,128 119.8 (112.9-127.0) 50.5
See page 18 for footnotes.
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TABLE 3. (Continued) Invasive colorectal cancer incidence* among women aged >50 years, by stage, age, and race/ethnicity —  United States,1 
2004-2006
Age group at diagnosis (yrs)
Localized5 Regional5 Distant5 Unstaged
No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI)
All races/ethnicities (continued)
>50 76,406 55.2 (54.8-55.6) 64,569 46.5 (46.2-46.9) 33,019 23.8 (23.6-24.1) 17,289 11.7 (11.5-11.9)
50-59 12,449 22.4 (22.0-22.8) 10,593 19.0 (18.6-19.4) 6,375 11.4 (11.1-11.7) 1,927 3.5 (3.3-3.6)
60-69 16,472 47.4 (46.6-48.1) 14,126 40.6 (39.9-41.2) 7,712 22.1 (21.6-22.6) 2,315 6.7 (6.4-6.9)
70-79 23,683 90.9 (89.7-9.02) 19,441 74.6 (73.5-75.6) 9,223 35.4 (34.7-36.2) 3,792 14.5 (14.0-15.0)
>80 23,802 119.2 (117.7-120.7) 20,409 102.1 (100.7-103.5) 9,709 48.5 (47.5-49.5) 9,255 45.1 (44.2-46.1)
White
>50 64,900 54.2 (53.8-54.6) 54,971 45.8 (45.4-46.2) 27,222 22.8 (22.5-23.0) 14,323 11.0 (10.8-11.2)
50-59 9,481 20.6 (20.2-21.0) 8,224 17.8 (17.4-18.2) 4,873 10.6 (10.3-10.9) 1,332 2.9 (2.7-3.1)
60-69 13,449 45.7 (45.0-46.5) 11,536 39.2 (38.5-39.9) 6,157 20.8 (20.3-21.4) 1,774 6.0 (5.8-6.3)
70-79 20,389 90.3 (89.1-91.6) 16,705 74.0 (72.9-75.1) 7,737 34.3 (33.6-35.1) 3,140 13.9 (13.4-14.4)
>80 21,581 121.0 (119.4-122.6) 18,506 103.7 (102.2-105.2) 8,455 47.3 (46.3-48.3) 8,077 44.0 (43.0-45.0)
Black
>50 8,319 61.1 (59.8-62.4) 7,014 51.5 (50.3-52.7) 4,676 34.1 (33.2-35.1) 2,135 15.8 (15.1-16.5)
50-59 2,122 32.0 (30.6-33.4) 1,762 26.6 (25.3-27.8) 1,228 18.5 (17.5-19.6) 378 5.7 (5.1-6.3)
60-69 2,240 59.8 (57.4-62.4) 1,947 51.9 (49.7-54.3) 1,239 33.0 (31.2-34.9) 374 10.0 (9.0-11.1)
70-79 2,345 94.6 (90.8-98.5) 1,959 79.0 (75.6-82.6) 1,200 48.4 (45.7-51.2) 472 19.1 (17.4-20.9)
>80 1,612 101.9 (97.0-107.0) 1,346 85.0 (80.5-89.7) 1,009 63.6 (59.7-67.7) 911 56.5 (52.8-60.3)
American Indian/Alaska Native
>50 270 34.5 (30.4-39.0) 250 31.9 (27.9-36.2) 142 17.1 (14.3-20.3) 51 7.1 (5.2-9.3)
50-59 67 14.4 (11.2-18.3) 62 13.3 (10.2-1.07) 50 10.7 (8.0-14.2) ! ! !
60-69 76 32.2 (25.3-40.3) 71 30.2 (23.5-38.1) 39 16.3 (11.6-22.3) ! ! !
70-79 87 66.2 (53.0-81.7) 73 55.6 (43.6-70.0) 32 24.6 (16.8-34.7) 16 12.1 (6.9-19.7)
>80 40 50.9 (36.3-69.3) 44 55.7 (40.4-74.8) 21 26.8 (16.6-41.0) 18 22.7 (13.4-35.9)
Asian/Pacific Islander
>50 1,934 40.4 (38.6-42.3) 1,893 39.8 (38.0-41.6) 833 17.4 (16.2-18.6) 306 6.7 (6.0-7.6)
50-59 499 19.6 (17.9-21.3) 456 17.8 (16.2-19.5) 197 7.7 (6.6-8.8) 70 2.8 (2.2-3.5)
60-69 474 34.0 (31.0-37.3) 476 34.2 (31.2-37.4) 238 17.1 (15.0-19.4) 53 3.8 (2.8-5.0)
70-79 579 64.7 (59.5-70.2) 564 63.0 (57.9-68.4) 211 23.5 (20.4-26.9) 62 7.0 (5.4-9.0)
>80 382 81.4 (73.4-90.0) 397 84.4 (76.3-93.2) 187 39.7 (34.2-45.9) 121 26.0 (21.6-31.0)
Hispanic
>50 3,649 40.2 (38.9-41.5) 3,632 40.0 (38.7-41.3) 1,872 20.2 (19.3-21.1) 894 10.4 (9.7-11.1)
50-59 823 17.3 (16.1-18.5) 837 17.6 (16.4-18.8) 541 11.4 (10.4-12.4) 141 3.0 (2.5-3.5)
60-69 1,016 38.4 (36.1-40.8) 986 37.2 (34.9-39.6) 488 18.4 (16.8-20.2) 155 5.9 (5.0-6.9)
70-79 1,072 64.1 (60.3-68.0) 1,032 61.7 (58.0-65.6) 492 29.3 (26.8-32.1) 232 13.9 (12.2-15.8)
>80 738 78.4 (72.8-84.3) 777 82.5 (76.8-88.5) 351 37.3 (33.5-41.4) 366 38.7 (34.8-42.9)
Abbreviation: CI = confidence interval.
Source: CDC's National Program of Cancer Registries (NPCR) and the National Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard population; 95% confidence intervals were calculated as modified gamma intervals (37). 
f Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
§ A localized cancer is one that is confined to the primary site, a regional cancer is one that has spread directly beyond the primary site or to regional lymph nodes, 
and a distant cancer is one that has spread to other organs 
1 Data not reported when case count is <16.
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TABLE 4. Number and percentage of women who received 
recommended colorectal cancer screening* —  Behavorial Risk 




Overall 114,422 62.0 (61.5-62.5)
Age at screening (yrs)
50-59 51,685 53.6 (52.8-54.4)
60-69 45,707 68.8 (68.0-69.6)
70-75 17,735 73.9 (72.7-75.0)
Race
White 99,513 62.9 (62.4-63.4)
Black 9,437 61.0 (59.1-62.9)
American Indian/Alaska Native 1,684 53.9 (49.1-58.7)
Asian/Pacific Islander 1,621 56.4 (51.2-61.5)
Ethnicity
Hispanic 4,704 51.0 (48.3-53.8)
Non-Hispanic 109,996 63.0 (62.5-63.5)
Abbreviation: CI = confidence interval.
* Determined by having met the U.S. Preventive Services Task Force recom­
mendation of having a fecal occult blood test in the preceding year, a flexible 
sigmoidoscopy in the preceding 5 years, or a colonoscopy in the preceding 
10 years (74).
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TABLE 5. Invasive breast cancer incidence* among women aged >50 years, by stage, age, and race/ethnicity —  United States,1 2004-2006
Age group at diagnosis (yrs)
Overall Late (Regional + Distant)5
No. Rate (95% CI) No. Rate (95% CI) %
All races/ethnicities
>50 439,142 323.0 (322.0-323.9) 147,430 108.5 (108.0-109.1) 33.6
50-59 134,412 241.8 (240.5-243.1) 51,583 93.0 (92.2-93.8) 38.4
60-69 124,753 355.6 (353.6-357.6) 41,903 119.2 (118.1-120.4) 33.6
70-79 105,742 407.1 (404.6-409.5) 32,168 123.9 (122.6-125.3) 30.4
>80 74,235 373.8 (371.1-376.5) 21,776 109.7 (108.3-111.2) 29.3
White
>50 380,420 328.4 (327.3-329.4) 124,252 107.6 (107.0-108.2) 32.7
50-59 111,851 243.5 (242.0-244.9) 41,827 91.2 (90.4-92.1) 37.4
60-69 107,764 363.3 (361.1-365.5) 35,326 118.9 (117.6-120.1) 32.8
70-79 93,679 417.1 (414.4-419.8) 27,771 123.7 (122.3-125.2) 29.6
>80 67,126 378.7 (375.9-381.6) 19,328 109.1 (107.6-110.7) 28.8
Black
>50 41,843 295.7 (292.8-298.5) 17,757 124.3 (122.4-126.1) 42.4
50-59 15,675 236.4 (232.7-240.1) 7,279 109.8 (107.3-112.3) 46.4
60-69 12,029 319.6 (313.9-325.3) 5,037 133.6 (130.0-137.4) 41.9
70-79 8,840 355.9 (348.5-363.4) 3,490 140.5 (135.9-145.3) 39.5
>80 5,299 334.9 (325.9-344.1) 1,951 123.4 (118.0-129.0) 36.8
American Indian/Alaska Native
>50 1,489 172.1 (163.2-181.4) 544 61.4 (56.2-67.0) 36.5
50-59 562 120.7 (110.9-131.1) 227 48.8 (42.7-55.6) 40.4
60-69 477 197.0 (179.7-215.6) 171 70.7 (60.4-82.2) 35.8
70-79 295 223.5 (198.7-250.6) 91 68.5 (55.1-84.2) 30.8
>80 155 198.1 (168.1-232.0) 55 70.3 (52.9-91.6) 35.5
Asian/Pacific Islander
>50 10,563 199.4 (195.6-203.3) 3,598 67.1 (64.9-69.4) 34.1
50-59 4,620 180.8 (175.6-186.1) 1,714 67.2 (64.0-70.4) 37.1
60-69 3,130 221.6 (213.9-229.5) 1,005 71.0 (66.6-75.5) 32.1
70-79 1,948 216.1 (206.6-225.9) 601 66.8 (61.5-72.3) 30.9
>80 865 183.4 (171.3-196.0) 278 59.0 (52.3-66.4) 32.1
Hispanic
>50 23,305 238.1 (235.0-241.3) 8,739 87.8 (85.9-89.7) 37.5
50-59 9,045 190.2 (186.3-194.1) 3,770 79.3 (76.8-81.8) 41.7
60-69 7,032 264.0 (257.9-270.3) 2,579 96.6 (92.9-100.4) 36.7
70-79 4,901 291.4 (283.3-299.7) 1,649 98.0 (93.3-102.9) 33.6
>80 2,327 247.3 (237.4-257.6) 741 78.8 (73.2-84.7) 31.8
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TABLE 5. (Continued) Invasive breast cancer incidence* among women aged >50 years, by stage, age, and race/ethnicity —  United States,1 
2004-2006
Age group at diagnosis 
(yrs)
Localized5 Regional5 Distant5 Unstaged
No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI)
All races/ethnicities (continued)
>50 270,898 199.9 (199.1-200.6) 124,308 91.6 (91.1-92.1) 23,122 16.9 (16.7-17.1) 20,812 14.6 (14.4-14.8)
50-59 78,682 141.3 (140.4-142.3) 44,758 80.7 (80.0-81.5) 6,825 12.2 (12.0-12.5) 4,146 7.5 (7.2-7.7)
60-69 78,532 224.0 (222.5-225.6) 35,539 101.1 (100.1-102.2) 6,364 18.1 (17.7-18.6) 4,317 12.3 (12.0-12.7)
70-79 68,981 265.6 (263.6-267.6) 26,634 102.6 (101.4-103.8) 5,534 21.3 (20.7-21.9) 4,593 17.6 (17.1-18.1)
>80 44,703 226.1 (224.0-228.2) 17,377 87.6 (86.3-88.9) 4,399 22.1 (21.5-22.8) 7,756 38.0 (37.1-38.8)
White
>50 238,740 206.6 (205.8-207.5) 105,272 91.4 (90.8-91.9) 18,980 16.3 (16.0-16.5) 17,426 14.1 (13.9-14.3)
50-59 66,787 145.2 (144.1-146.3) 36,546 79.8 (79.0-80.6) 5,281 11.5 (11.2-11.8) 3,236 7.0 (6.8-7.3)
60-69 68,926 232.5 (230.8-234.3) 30,109 101.3 (100.2-102.5) 5,217 17.6 (17.1-18.0) 3,511 11.9 (11.5-12.3)
70-79 61,994 276.0 (273.9-278.2) 23,148 103.1 (101.8-104.5) 4,623 20.6 (20.0-21.2) 3,914 17.3 (16.8-17.9)
>80 41,033 232.6 (230.3-234.8) 15,469 87.4 (86.0-88.8) 3,859 21.7 (21.0-22.4) 6,765 37.0 (36.1-37.9)
Black
>50 21,845 155.2 (153.1-157.3) 14,356 100.1 (98.5-101.8) 3,401 24.1 (23.3-25.0) 2,241 16.2 (15.6-16.9)
50-59 7,831 118.1 (115.5-120.7) 6,033 91.0 (88.7-93.3) 1,246 18.8 (17.7-19.8) 565 8.5 (7.8-9.3)
60-69 6,479 172.3 (168.1-176.5) 4,095 108.6 (105.3-112.0) 942 25.1 (23.5-26.7) 513 13.6 (12.5-14.9)
70-79 4,890 196.8 (191.3-202.4) 2,724 109.7 (105.6-113.9) 766 30.9 (28.7-33.1) 460 18.6 (16.9-20.4)
>80 2,645 168.0 (161.7-174.6) 1,504 95.2 (90.5-100.2) 447 28.2 (25.7-31.0) 703 43.4 (40.3-46.8)
American Indian/Alaska Native
>50 840 97.8 (91.0-104.9) 457 51.0 (46.3-56.1) 87 10.4 (8.3-12.9) 105 12.9 (10.5-15.7)
50-59 308 66.1 (58.9-73.9) 198 42.6 (36.9-49.0) 29 6.2 (4.2-8.9) 27 5.8 (3.8-8.5)
60-69 272 112.3 (99.3-126.6) 142 58.5 (49.3-69.1) 29 12.1 (8.1-17.5) 34 14.0 (9.7-19.6)
70-79 184 139.9 (120.4-161.7) 75 55.9 (43.9-70.1) 16 12.6 (7.2-20.5) 20 15.1 (9.2-23.3)
>80 76 97.3 (76.6-121.9) 42 53.8 (38.7-72.8) ! ! ! 24 30.5 (19.5-45.4)
Asian/Pacific Islander
>50 6,691 126.8 (123.7-129.9) 3,121 58.0 (55.9-60.1) 477 9.1 (8.3-10.0) 274 5.5 (4.9-6.2)
50-59 2,810 109.9 (105.9-114.0) 1,507 59.1 (56.1-62.1) 207 8.1 (7.0-9.3) 96 3.7 (3.0-4.6)
60-69 2,053 145.6 (139.3-152.0) 876 61.8 (57.8-66.1) 129 9.1 (7.6-10.8) 72 5.1 (4.0-6.4)
70-79 1,304 144.6 (136.8-152.6) 511 56.6 (51.8-61.8) 90 10.1 (8.1-12.4) 43 4.8 (3.5-6.4)
>80 524 110.7 (101.4-120.6) 227 48.2 (42.1-54.9) 51 10.8 (8.1-14.2) 63 13.6 (10.5-17.5)
Hispanic
>50 13,411 137.9 (135.6-140.3) 7,461 74.5 (72.8-76.2) 1,278 13.3 (12.5-14.0) 1,155 12.4 (11.7-13.2)
50-59 4,936 103.8 (100.9-106.7) 3,326 69.9 (67.6-72.4) 444 9.3 (8.5-10.2) 339 7.1 (6.4-7.9)
60-69 4,157 156.4 (151.6-161.2) 2,191 82.1 (78.7-85.6) 388 14.5 (13.1-16.1) 296 11.1 (9.9-12.4)
70-79 3,003 178.5 (172.2-185.0) 1,377 81.8 (77.5-86.3) 272 16.2 (14.3-18.2) 249 14.9 (13.1-16.9)
>80 1,315 139.8 (132.4-147.6) 567 60.4 (55.5-65.5) 174 18.5 (15.8-21.4) 271 28.7 (25.4-32.3)
Abbreviation: CI = confidence interval.
Source: CDC's National Program of Cancer Registries (NPCR) and the National Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard population; 95% confidence intervals were calculated as modified gamma intervals (37). 
f Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
§ A localized cancer is one that is confined to the primary site, a regional cancer is one that has spread directly beyond the primary site or to regional lymph nodes, 
and a distant cancer is one that has spread to other organs.
1 Data not reported when case count is <16.
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TABLE 6. Number and percentage of women aged 50-74 years who 
received recommended breast cancer screening* —  Behavioral 




Overall 116,708 81.2 (80.7-81.6)
Age at screening (yrs)
50-59 52,421 79.9 (79.3-80.5)
60-69 46,711 82.4 (81.8-83.0)
70-74 18,318 82.7 (81.7-83.7)
Race
White 101,245 81.4 (81.0-81.8)
Black 9,805 82.2 (80.5-83.7)
American Indian/Alaska Native 1,736 70.4 (65.6-74.8)
Asian/Pacific Islander 1,665 80.4 (75.9-84.3)
Ethnicity
Hispanic 4,886 81.4 (79.1-83.4)
Non-Hispanic 112,115 81.1 (80.7-81.5)
Abbreviation: CI = confidence interval.
* Determined by having met the U.S. Preventive Services Task Force recom­
mendation of having had a mammogram in the past 2 years (19).
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TABLE 7. Invasive cervical cancer incidence* among women aged >20 years, by stage, age, and race/ethnicity —  United States,1 2004-2006
Age group at diagnosis (yrs)
Overall Late (Regional + Distant)5
No. Rate (95% CI) No. Rate (95% CI) %
All races/ethnicities
>20 36,076 11.4 (11.2-11.5) 16,947 5.2 (5.1-5.3) 47.0
20-29 1,982 3.5 (3.3-3.6) 458 0.8 (0.7-0.9) 23.1
30-39 7,501 12.8 (12.5-13.1) 2,408 4.1 (4.0-4.3) 32.1
40-49 9,588 14.6 (14.3-14.9) 4,183 6.3 (6.1-6.5) 43.7
50-59 7,045 12.8 (12.5-13.1) 4,011 7.2 (7.0-7.5) 57.0
60-69 4,715 13.4 (13.0-13.8) 2,769 7.9 (7.6-8.2) 58.8
70-79 3,129 12.1 (11.7-12.5) 1,897 7.3 (7.0-7.6) 60.6
>80 2,116 10.6 (10.2-11.1) 1,221 6.2 (5.8-6.5) 57.7
White
>20 27,932 10.9 (10.7-11.0) 12,949 4.9 (4.8-4.9) 46.4
20-29 1,591 3.6 (3.4-3.8) 353 0.8 (0.7-0.9) 22.2
30-39 6,073 13.3 (13.0-13.6) 1,909 4.2 (4.0-4.4) 31.5
40-49 7,381 14.0 (13.7-14.3) 3,142 5.9 (5.7-6.1) 42.6
50-59 5,410 11.9 (11.6-12.2) 3,111 6.8 (6.6-7.1) 57.5
60-69 3,570 12.0 (11.6-12.4) 2,112 7.1 (6.8-7.4) 59.2
70-79 2,286 10.2 (9.8-10.6) 1,394 6.2 (5.9-6.6) 61.0
>80 1,621 9.1 (8.7-9.6) 928 5.2 (4.9-5.6) 57.3
Black
>20 5,694 14.7 (14.3-15.0) 3,003 7.8 (7.5-8.1) 52.8
20-29 262 2.9 (2.6-3.3) 86 1.0 (0.8-1.2) 32.8
30-39 947 11.1 (10.4-11.9) 374 4.4 (4.0-4.9) 39.6
40-49 1,519 16.9 (16.1-17.8) 780 8.7 (8.1-9.3) 51.4
50-59 1,147 17.3 (16.3-18.3) 678 10.2 (9.5-11.0) 59.1
60-69 828 22.0 (20.5-23.5) 484 12.8 (11.7-14.0) 58.5
70-79 606 24.4 (22.5-26.5) 374 15.1 (13.6-16.7) 61.7
>80 385 24.2 (21.9-26.8) 227 14.3 (12.5-16.3) 59.0
American Indian/Alaska Native
>20 240 8.9 (7.8-10.1) 113 4.4 (3.6-5.3) 47.3
20-29 22 3.3 (2.1-5.0) ! ! ! **
30-39 63 10.8 (8.3-13.8) 19 3.3 (2.0-5.1) 30.2
40-49 67 10.7 (8.3-13.6) 33 5.3 (3.6-7.4) 49.3
50-59 40 8.6 ! 24 5.2 (3.3-7.7) 60.0
60-69 27 10.9 ! 18 7.3 (4.3-11.6) 66.7
70-79 ! ! ! ! ! ! **
>80 ! ! ! ! ! ! **
Asian/Pacific Islander
>20 1,532 10.5 (10.0-11.0) 742 5.2 (4.9-5.6) 48.4
20-29 34 1.0 (0.7-1.4) ! ! ! **
30-39 236 6.2 (5.5-7.1) 79 2.1 (1.7-2.6) 33.5
40-49 448 13.5 (12.3-14.8) 189 5.7 (4.9-6.6) 42.2
50-59 330 12.9 (11.6-14.4) 167 6.5 (5.6-7.6) 50.6
60-69 229 16.2 (14.2-18.4) 135 9.6 (8.0-11.3) 59.0
70-79 174 19.3 (16.6-22.4) 109 12.2 (10.0-14.7) 62.6
>80 81 17.1 (13.6-21.3) 52 11.0 (8.2-14.4) 64.2
Hispanic
>20 5,632 17.2 (16.8-17.7) 2,585 8.4 (8.0-8.7) 45.9
20-29 388 3.8 (3.5-4.2) 102 1.0 (0.8-1.2) 26.3
30-39 1,384 14.8 (14.0-15.6) 476 5.1 (4.7-5.6) 34.4
40-49 1,591 21.1 (20.1-22.2) 722 9.6 (8.9-10.3) 45.4
50-59 1,022 21.5 (20.2-22.9) 557 11.7 (10.8-12.7) 54.5
60-69 639 24.0 (22.2-25.9) 376 14.1 (12.7-15.6) 58.8
70-79 403 23.9 (21.6-26.4) 227 13.5 (11.8-15.4) 56.3
>80 205 21.8 (18.9-25.0) 125 13.3 (11.1-15.8) 61.0
See page 24 for footnotes.
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TABLE 7. (Continued) Invasive cervical cancer incidence* among women aged >20 years, by stage, age, and race/ethnicity —  United States,1 
2004-2006
Localized5 Regional5 Distant5 Unstaged
Age group at diagnosis (yrs) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI)
All races/ethnicities (continued)
>20 16,298 5.3 (5.2-5.4) 13,003 4.0 (4.0-4.1) 3,944 1.2 (1.2-1.2) 2,808 0.9 (0.8-0.9)
20-29 1,307 2.3 (2.2-2.4) 388 0.7 (0.6-0.7) 70 0.1 (0.1-0.2) 215 0.4 (0.3-0.4)
30-39 4,632 7.9 (7.7-8.1) 2,018 3.5 (3.3-3.6) 390 0.7 (0.6-0.7) 455 0.8 (0.7-0.9)
40-49 4,931 7.5 (7.3-7.8) 3,284 5.0 (4.8-5.1) 899 1.4 (1.3-1.4) 467 0.7 (0.6-0.8)
50-59 2,579 4.7 (4.5-4.9) 2,956 5.3 (5.2-5.5) 1,055 1.9 (1.8-2.0) 453 0.8 (0.7-0.9)
60-69 1,544 4.4 (4.2-4.6) 2,026 5.8 (5.5-6.0) 743 2.1 (2.0-2.3) 398 1.1 (1.0-1.3)
70-79 864 3.3 (3.1-3.6) 1,413 5.4 (5.2-5.7) 484 1.9 (1.7-2.0) 367 1.4 (1.3-1.6)
>80 441 2.2 (2.0-2.4) 918 4.6 (4.3-4.9) 303 1.5 (1.4-1.7) 453 2.2 (2.0-2.4)
White
>20 12,955 5.2 (5.2-5.3) 9,902 3.7 (3.7-3.8) 3,047 1.1 (1.1-1.2) 2,011 0.7 (0.7-0.8)
20-29 1,075 2.4 (2.3-2.6) 294 0.7 (0.6-0.7) 59 0.1 (0.1-0.2) 162 0.4 (0.3-0.4)
30-39 3,835 8.4 (8.1-8.7) 1,594 3.5 (3.3-3.7) 315 0.7 (0.6-0.8) 325 0.7 (0.6-0.8)
40-49 3,917 7.5 (7.2-7.7) 2,460 4.6 (4.5-4.8) 682 1.3 (1.2-1.4) 316 0.6 (0.5-0.7)
50-59 1,982 4.4 (4.2-4.6) 2,269 5.0 (4.8-5.2) 842 1.8 (1.7-2.0) 315 0.7 (0.6-0.8)
60-69 1,186 4.0 (3.8-4.2) 1,556 5.2 (5.0-5.5) 556 1.9 (1.7-2.0) 269 0.9 (0.8-1.0)
70-79 627 2.8 (2.6-3.0) 1,044 4.7 (4.4-5.0) 350 1.6 (1.4-1.7) 265 1.2 (1.0-1.3)
>80 333 1.9 (1.7-2.1) 685 3.9 (3.6-4.2) 243 1.4 (1.2-1.6) 359 2.0 (1.8-2.2)
Black
>20 2,181 5.5 (5.3-5.7) 2,274 5.9 (5.6-6.1) 729 1.9 (1.8-2.1) 506 1.3 (1.2-1.5)
20-29 149 1.7 (1.4-2.0) 79 0.9 (0.7-1.1) ! ! ! 27 0.3 (0.2-0.4)
30-39 502 5.9 (5.4-6.4) 313 3.7 (3.3-4.1) 61 0.7 (0.6-0.9) 69 0.8 (0.6-1.0)
40-49 641 7.2 (6.6-7.7) 610 6.8 (6.2-7.3) 170 1.9 (1.6-2.2) 97 1.1 (0.9-1.3)
50-59 394 6.0 (5.4-6.6) 502 7.6 (6.9-8.3) 176 2.7 (2.3-3.1) 75 1.1 (0.9-1.4)
60-69 256 6.8 (6.0-7.7) 329 8.7 (7.8-9.7) 155 4.1 (3.5-4.8) 87 2.3 (1.9-2.9)
70-79 157 6.3 (5.4-7.4) 265 10.7 (9.4-12.1) 109 4.4 (3.6-5.3) 75 3.0 (2.4-3.8)
>80 82 5.2 (4.1-6.5) 176 11.1 (9.5-12.9) 51 3.2 (2.4-4.2) 76 4.7 (3.7-5.9)
American Indian/Alaska Native
>20 112 3.9 (3.2-4.7) 92 3.5 (2.8-4.3) 21 0.8 (0.5-1.3) ! ! !
20-29 16 2.4 (1.4-3.9) ! ! ! ! ! ! ! ! !
30-39 41 7.0 (5.0-9.5) 18 3.1 (1.8-4.9) ! ! ! ! ! !
40-49 33 5.3 (3.6-7.4) 25 4.0 (2.6-5.9) ! ! ! ! ! !
50-59 ! ! ! 19 4.1 (2.5-6.4) ! ! ! ! ! !
60-69 ! ! ! 16 6.4 (3.7-10.5) ! ! ! ! ! !
70-79 ! ! ! ! ! ! ! ! ! ! ! !
>80 ! ! ! ! ! ! ! ! ! ! ! !
Asian/Pacific Islander
>20 710 4.7 (4.3-5.1) 609 4.3 (4.0-4.7) 133 0.9 (0.8-1.1) 80 0.6 (0.4-0.7)
20-29 20 0.6 (0.4-0.9) ! ! ! ! ! ! ! ! !
30-39 148 3.9 (3.3-4.6) 69 1.8 (1.4-2.3) ! ! ! ! ! !
40-49 241 7.3 (6.4-8.2) 152 4.6 (3.9-5.4) 37 1.1 (0.8-1.5) 18 0.5 (0.3-0.9)
50-59 141 5.5 (4.7-6.5) 137 5.4 (4.5-6.3) 30 1.2 (0.8-1.7) 22 0.9 (0.5-1.3)
60-69 79 5.5 (4.4-6.9) 109 7.8 (6.4-9.4) 26 1.8 (1.2-2.7) ! ! !
70-79 59 6.5 (4.9-8.4) 88 9.8 (7.8-12.0) 21 2.4 (1.5-3.6) ! ! !
>80 22 4.7 (2.9-7.0) 46 9.7 (7.1-13.0) ! ! ! ! ! !
Hispanic
>20 2,644 7.5 (7.2-7.8) 2,122 6.8 (6.5-7.1) 463 1.5 (1.4-1.7) 402 1.3 (1.2-1.5)
20-29 244 2.4 (2.1-2.7) 80 0.8 (0.6-1.0) 22 0.2 (0.1-0.3) 42 0.4 (0.3-0.6)
30-39 824 8.8 (8.2-9.4) 410 4.4 (4.0-4.9) 66 0.7 (0.5-0.9) 83 0.9 (0.7-1.1)
40-49 799 10.6 (9.9-11.4) 597 8.0 (7.3-8.6) 125 1.7 (1.4-2.0) 70 0.9 (0.7-1.2)
50-59 397 8.4 (7.5-9.2) 456 9.6 (8.7-10.5) 101 2.1 (1.7-2.6) 68 1.4 (1.1-1.8)
60-69 222 8.3 (7.3-9.5) 303 11.4 (10.1-12.7) 73 2.7 (2.2-3.5) 41 1.5 (1.1-2.1)
70-79 119 7.0 (5.8-8.4) 184 10.9 (9.4-12.6) 43 2.6 (1.9-3.5) 57 3.4 (2.5-4.4)
>80 39 4.2 (3.0-5.7) 92 9.8 (7.9-12.0) 33 3.5 (2.4-4.9) 41 4.4 (3.1-5.9)
Abbreviation: CI = confidence interval.
Source: CDC's National Program of Cancer Registries (NPCR) and the National Cancer Surveillance, Epidemiology, and End Results (SEER) program.
* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard population; 95% confidence intervals were calculated as modified gamma intervals (37). 
f Data from NPCR and SEER registries meet U.S. Cancer Statistics publication criteria for 2004-2006 and cover approximately 96.1% of the U.S. population (29).
§ A localized cancer is one that is confined to the primary site, a regional cancer is one that has spread directly beyond the primary site or to regional lymph nodes, 
and a distant cancer is one that has spread to other organs.
1 Data not reported when case count <16.
** Statistic could not be calculated.
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TABLE 8. Number and percentage of women who received recom­
mended cervical cancer screening* —  Behavioral Risk Factor Sur­




Overall 129,008 87.6 (87.2-87.9)
Age at screening (yrs)
21-29 14,551 87.2 (86.0-88.2)
30-39 29,421 90.7 (90.1-91.3)
40-49 34,759 87.8 (87.2-88.4)
50-59 36,034 86.0 (85.3-86.6)
60-64 15,223 83.1 (82.0-84.3)
Race
White 105,937 88.0 (87.6-88.4)
Black 12,137 88.8 (87.6-89.8)
American Indian/Alaska Native 2,464 82.9 (79.2-86.0)
Asian/Pacific Islander 3,380 80.3 (77.4-83.0)
Ethnicity
Hispanic 10,013 87.3 (85.9-88.5)
Non-Hispanic 119,646 87.6 (87.2-88.0)
Abbreviation: CI = confidence interval.
* Determined by having met the U.S. Preventive Services Task Force recom­
mendation of having had a Pap test in the preceding 3 years (25).
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